JP2022503792A5 - - Google Patents
Info
- Publication number
- JP2022503792A5 JP2022503792A5 JP2021516496A JP2021516496A JP2022503792A5 JP 2022503792 A5 JP2022503792 A5 JP 2022503792A5 JP 2021516496 A JP2021516496 A JP 2021516496A JP 2021516496 A JP2021516496 A JP 2021516496A JP 2022503792 A5 JP2022503792 A5 JP 2022503792A5
- Authority
- JP
- Japan
- Prior art keywords
- caution
- optionally substituted
- alkyl
- independently
- membered heterocycles
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736974P | 2018-09-26 | 2018-09-26 | |
| US62/736,974 | 2018-09-26 | ||
| PCT/US2019/053015 WO2020069027A1 (en) | 2018-09-26 | 2019-09-25 | Treatment of hematological malignancies with inhibitors of menin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022503792A JP2022503792A (ja) | 2022-01-12 |
| JP2022503792A5 true JP2022503792A5 (https=) | 2022-10-04 |
| JPWO2020069027A5 JPWO2020069027A5 (https=) | 2022-10-04 |
Family
ID=69949505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516496A Pending JP2022503792A (ja) | 2018-09-26 | 2019-09-25 | メニン阻害剤を用いた血液悪性腫瘍の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230095934A1 (https=) |
| EP (1) | EP3856173A4 (https=) |
| JP (1) | JP2022503792A (https=) |
| CN (1) | CN113164443A (https=) |
| WO (1) | WO2020069027A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017192543A1 (en) | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| EP3805215A1 (en) | 2016-06-10 | 2021-04-14 | Vitae Pharmaceuticals, LLC | Inhibitors of the menin-mll interaction |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| CA3058448A1 (en) | 2017-03-31 | 2018-10-04 | The Regents Of The University Of Michigan | Piperidines as covalent menin inhibitors |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| JP7554829B2 (ja) | 2019-12-19 | 2024-09-20 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換直鎖スピロ誘導体 |
| MX2022012471A (es) | 2020-04-07 | 2022-11-30 | Syndax Pharmaceuticals Inc | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. |
| CN114478568A (zh) * | 2020-10-27 | 2022-05-13 | 苏州优理生物医药科技有限公司 | 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用 |
| CN117177744A (zh) | 2021-01-29 | 2023-12-05 | 塞迪拉治疗股份有限公司 | Cdk2抑制剂及其使用方法 |
| EP4334320A1 (en) * | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| MX2023013174A (es) | 2021-05-08 | 2023-11-30 | Janssen Pharmaceutica Nv | Derivados espiro sustituidos. |
| MX2023013436A (es) * | 2021-05-11 | 2023-12-12 | Janssen Pharmaceutica Nv | Terapias de combinacion. |
| TW202311262A (zh) | 2021-05-14 | 2023-03-16 | 美商錫達斯醫藥股份有限公司 | Menin-mll交互作用之抑制劑 |
| WO2022253167A1 (en) | 2021-06-01 | 2022-12-08 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES |
| CN117425659A (zh) | 2021-06-03 | 2024-01-19 | 詹森药业有限公司 | 哒嗪或被螺环胺取代的1,2,4-三嗪 |
| WO2022257047A1 (en) * | 2021-06-09 | 2022-12-15 | Acerand Therapeutics (Hong Kong) Limited | Diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof |
| CA3220099A1 (en) | 2021-06-17 | 2022-12-22 | Wei Cai | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cance |
| MX2023015436A (es) | 2021-06-26 | 2024-02-21 | Cedilla Therapeutics Inc | Inhibidores de cdk2 y metodos de uso de los mismos. |
| CN118234497A (zh) * | 2021-12-15 | 2024-06-21 | 丹娜-法伯癌症研究所 | 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist) |
| WO2023150635A1 (en) * | 2022-02-04 | 2023-08-10 | Kura Oncology, Inc. | Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| TW202415660A (zh) * | 2022-09-02 | 2024-04-16 | 大陸商和記黃埔醫藥（上海）有限公司 | 三嗪類化合物及其用途 |
| CN120456907A (zh) * | 2022-11-02 | 2025-08-08 | 库拉肿瘤学公司 | 急性白血病的治疗方法 |
| WO2024112819A1 (en) * | 2022-11-22 | 2024-05-30 | Dana-Farber Cancer Institute, Inc. | Men1 mutations and uses thereof |
| CN120529900A (zh) * | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| CN118994033B (zh) * | 2023-05-17 | 2025-09-16 | 成都先导药物开发股份有限公司 | 一种sdnx-5613的合成方法及其中间体化合物 |
| KR20260039698A (ko) * | 2023-07-17 | 2026-03-20 | 쿠라 온콜로지, 인크. | 결정 형태의 메닌 억제제 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017514505A (ja) * | 2014-05-07 | 2017-06-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 急性骨髄性白血病の新規バイオマーカー |
| WO2016040330A1 (en) * | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| AR104020A1 (es) * | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| AU2016324920B2 (en) * | 2015-09-14 | 2022-03-03 | Brunangelo Falini | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia |
| EP4643952A3 (en) * | 2016-01-26 | 2026-01-14 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1 |
| CN109152784B (zh) * | 2016-03-16 | 2021-12-28 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
| CN109640987B (zh) * | 2016-03-16 | 2022-12-02 | 库拉肿瘤学公司 | Menin-mll的桥联双环抑制剂及使用方法 |
| WO2017192543A1 (en) * | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| CA2937896A1 (en) * | 2016-08-02 | 2018-02-02 | Universite De Montreal | Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia |
| WO2018024602A1 (en) * | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| BR112019008762A2 (pt) * | 2016-11-02 | 2019-07-16 | Arog Pharmaceuticals, Inc. | método para o tratamento de um distúrbio proliferativo mutado em flt3 |
| WO2018106820A1 (en) * | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| US10703757B2 (en) * | 2016-12-23 | 2020-07-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
| CN110691779B (zh) * | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
-
2019
- 2019-09-25 EP EP19867072.1A patent/EP3856173A4/en active Pending
- 2019-09-25 CN CN201980078019.9A patent/CN113164443A/zh active Pending
- 2019-09-25 WO PCT/US2019/053015 patent/WO2020069027A1/en not_active Ceased
- 2019-09-25 JP JP2021516496A patent/JP2022503792A/ja active Pending
- 2019-09-26 US US17/278,527 patent/US20230095934A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022503792A5 (https=) | ||
| JPWO2020069027A5 (https=) | ||
| JP6952097B2 (ja) | ラミノパシー、老化及び癌を治療又は予防するためのｎａｔ１０モジュレーター | |
| CN104000806B (zh) | 端粒酶活化化合物及其使用方法 | |
| JP2020514388A5 (https=) | ||
| CN116354960A (zh) | Shp2磷酸酶抑制剂 | |
| US11654149B2 (en) | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | |
| JP2019521988A (ja) | 癌を処置するためのｅｚｈ２阻害剤 | |
| JP2018524298A (ja) | リンパ腫を処置するためのｅｚｈ２阻害剤 | |
| ZA200105399B (en) | Tricyclic inhibitors of poly(ADP-ribose) polymerases. | |
| WO2002069900A2 (en) | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors | |
| JP7747351B2 (ja) | ベンゼン環化合物及びその使用 | |
| CA3246041A1 (en) | Tetracyclic compound and its use | |
| EP0512817A1 (en) | Pyridazinedione derivatives, their preparation and pharmaceutical applications | |
| WO2018200571A1 (en) | Substituted 2,3-dihydro-1h-indene analogs and methods using same | |
| WO2021097075A1 (en) | Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| TW201139441A (en) | Substituted triazolo-pyrimidine compounds | |
| RU2025136491A (ru) | Производное 3,4-дигидрофталазин-1(2h)-она, способ его изготовления и его применение | |
| JP3718533B2 (ja) | ジヒドロキシフェニルスルフィド誘導体またはその塩を含む抗メラノーマ剤 | |
| EA047636B1 (ru) | Соединения и способы их применения | |
| WO2023002323A1 (en) | Synthesis of substituted tricyclic amides and analogues thereof | |
| AU2022399786A1 (en) | Compounds | |
| WO2024089272A1 (en) | New inhibitors of phosphatidylinositol 3-kinase | |
| HK40105830A (zh) | 用於治疗与核糖体障碍相关的贫血的组合物和方法 | |
| HK40087850A (zh) | Ezh2抑制剂用於治疗癌症的用途 |